Cerebrovascular complications of neurocysticercosis

Neurologist

Volumn 18, Issue 1, 2012, Pages 17-22

  Marquez, Juan Manuel ^a   Arauz, Antonio ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

cerebrovascular disease; cysticerci; Neurocysticercosis

Indexed keywords

ALBENDAZOLE; ANTICONVULSIVE AGENT; ANTIPARASITIC AGENT; CORTICOSTEROID; DEXAMETHASONE; GADOLINIUM; PLACEBO; PRAZIQUANTEL; PREDNISONE;

ANTICONVULSANT THERAPY; ARTERITIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROSPINAL FLUID CYTOLOGY; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CYSTICERCAL ARTERITIS; CYSTICERCOID; CYSTICERCOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; EOSINOPHILIA; EPIDEMIOLOGICAL DATA; HEADACHE; HISTOPATHOLOGY; HUMAN; HYDROCEPHALUS; INCIDENCE; INTERNAL CAROTID ARTERY OCCLUSION; METACESTODE; NEUROCYSTICERCOSIS; NEUROIMAGING; NEUROSURGERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SEIZURE; SEROLOGY; SEROPREVALENCE; STROKE; SUBARACHNOID HEMORRHAGE; SYMPTOM; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION;

ANTIPARASITIC AGENTS; ARTERITIS; HUMANS; NEUROCYSTICERCOSIS; RISK FACTORS; STROKE;

EID: 84855427391     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e31823d7a80     Document Type: Review

References (82)

1. Rajshekhar V, Joshi DD, Doanh NQ, et al. Taenia solium taeniosis/cysticercosis in Asia: epidemiology, impact and issues. Acta Trop. 2003;87:53-60. (Pubitemid 36637075)
2. Zoli A, Shey-Njila O, Assana E, et al. Regional status, epidemiology and impact of Taenia solium cysticercosis in Western and Central Africa. Acta Trop. 2003;87:35-42. (Pubitemid 36629482)
3. Bern C, Garcia HH, Evans C, et al. Magnitude of the disease burden from neurocysticercosis in a developing country. Clin In-fect Dis. 1999;29:1203-1209. (Pubitemid 30265640)
4. Flisser A, Sarti E, Lightowlers M, et al. Neurocysticercosis: regional status, epidemiology, impact and control measures in the Americas. Acta Trop. 2003;87:43-51. (Pubitemid 36629483)
5. Carpio A, Hauser WA. Epilepsy in the developing world. Curr Neurol Neurosci Rep. 2009;9:319-326.
6. Esquivel A, Diaz-Otero F, Gimenez-Roldan S. Growing frequency of neurocysticercosis in Madrid (Spain). Neurologia. 2005;20: 116-120. (Pubitemid 40592976)
7. Más-Sesé G, Vives-Piñera I, Fernández-Barreiro A, et al. A descriptive study of neurocysticercosis in a tertiary care hospital. Rev Neurol. 2008;46:194-196. (Pubitemid 351413972)
8. Willingham AL III, Harrison LJ, Fèvre EM, et al. Cysticercosis Working Group in Europe. Inaugural meeting of the Cysticercosis Working Group in Europe. Emerg Infect Dis. 2008;14:e2.
9. Figueroa JJ, Davis LE, Magalhaes A. Extraparenchymal Neuro-cysticercosis in Albuquerque, New Mexico. J Neuroimaging. 2011;21:38-43.
10. De la Garza Y, Graviss EA, Daver NG, et al. Epidemiology of neurocysticercosis in Houston, Texas. Am J Trop Med Hyg. 2005;73:766-770. (Pubitemid 41446727)
11. Wallin MT, Kurtzke JF. Neurocysticercosis in the United States: review of an important emerging infection. Neurology. 2004; 63:1559-1564. (Pubitemid 39507569)
12. Parija SC, Gireesh AR. A serological study of cysticercosis in patients with HIV. Rev Inst Med Trop Sao Paulo. 2009;51:185-189.
13. Alarcón F, Vanormelingen K, Moncayo J, et al. Cerebral cysticercosis as a risk factor for stroke in young and middle-aged people. Stroke. 1992;23:1563-1565.
14. Kumwenda JJ, Mateyu G, Kampondeni S, et al. Differential diagnosis of stroke in a setting ofhigh HIV prevalence in Blantyre, Malawi. Stroke. 2005;36:960-964. (Pubitemid 40629284)
15. Cantú C, Barinagarrementeria F. Cerebrovascular complications of neurocysticercosis. Clinical and neuroimaging spectrum. Arch Neurol. 1996;53:233-239. (Pubitemid 26077475)
16. Scharf D. Neurocysticercosis. Two hundred thirty-eight cases from a California hospital. Arch Neurol. 1988;45:777-780.
17. Manousakis G, Jensen MB, Chacon MR, et al. The interface between stroke and infectious disease: infectious diseases leading to stroke and infections complicating stroke. Curr Neurol Neurosci Rep. 2009;9:28-34.
18. White AC Jr. Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management. Annu Rev Med. 2000; 51:187-206.
19. Terrazas LI. The complex role of pro- and anti-inflammatory cytokines in cysticercosis: immunological lessons from exper-imental and natural hosts. Curr Top Med Chem. 2008;8:383-392. (Pubitemid 351791016)
20. Hernández-Mendoza L, Molinari JL, Garrido E, et al. The implantation of Taenia solium metacestodes in mice induces down-modulation of T-cell proliferation and cytokine production. Parasitol Res. 2005;95:256-265. (Pubitemid 40379466)
21. Ridaura Sanz C. Host response in childhood neurocysticercosis: some pathological aspects. Childs Nerv Syst. 1987;3:206-207.
22. Alvarez JI, Londoño DP, Alvarez AL, et al. Granuloma formation and parasite disintegration in porcine cysticercosis: comparison with human neurocysticercosis. J Comp Pathol. 2002;127: 186-193.
23. Alvarez JI, Teale JM. Evidence for differential changes of junctional complex proteins in murine neurocysticercosis depend-ent upon CNS vasculature. Brain Res. 2007;1169:98-111. (Pubitemid 47374095)
24. Rodriguez-Carbajal J, Del Brutto OH, Penagos P, et al. Occlusion of the middle cerebral artery due to cysticercotic angiitis. Stroke. 1989;20:1095-1099. (Pubitemid 19204027)
25. Kim IY, Kim TS, Lee JH, et al. Inflammatory aneurysm due to neurocysticercosis. J Clin Neurosci. 2005;12:585-588.
26. Barinagarrementeria F, Cantú C. Frequency ofcerebral arteritis in subarachnoid cysticercosis: an angiographic study. Stroke. 1998; 29:123-125. (Pubitemid 28046952)
27. Azad R, Gupta RK, Kumar S, et al. Is neurocysticercosis a risk factor in coexistent intracranial disease? An MRI based study. J Neurol Neurosurg Psychiatry. 2003;74:359-361. (Pubitemid 36259365)
28. Thaler DE, Frosch MP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 16-2002. A 41-year-old woman with global headache and an intracranial mass. NEngl JMed. 2002;346:1651-1658.
29. Finelli PF. Case 16-2002: neurocysticercosis. NEngl JMed. 2002; 347:1117.
30. Molinari JL, Garća-Mendoza E, de la Garza Y, et al. Discrim-ination between active and inactive neurocysticercosis by metacestode excretory/secretory antigens of Taenia solium in an enzyme-linked immunosorbent assay. Am J Trop Med Hyg. 2002; 66:777-781. (Pubitemid 35001055)
31. Sotelo J, Guerrero V, Rubio F. Neurocysticercosis: a new classification based on active and inactive forms. A study of 753 cases. Arch Intern Med. 1985;145:442-445. (Pubitemid 15140738)
32. Carpio A, Placencia M, Santillan F, et al. A proposal for classification ofneurocysticercosis. Can J Neurol Sci. 1994;21: 43-47.
33. Estanol B, Corona T, Abad P. A prognostic classification of cerebral cysticercosis: therapeutic implications. J Neurol Neuro-surg Psychiatry. 1986;49:1131-1134. (Pubitemid 16028694)
34. Arboix A, Mart́-Vilalta JL. New concepts in lacunar stroke etiology: the constellation of small-vessel arterial disease. Cerebrovasc Dis. 2004;17(Suppl 1):58-62. (Pubitemid 38032522)
35. Barinagarrementeria F, Del Brutto OH. Neurocysticercosis and pure motor hemiparesis. Stroke. 1988;19:1156-1158.
36. Barinagarrementeria F, Del Brutto OH. Lacunar syndrome due to neurocysticercosis. Arch Neurol. 1989;46:415-417. (Pubitemid 19099335)
37. Napon C, Ouédraogo D, Diallo O, et al. Wallenberg syndrome and neurocysticercosis: about one case in Ouagadougou, Burkina Faso. Bull Soc Pathol Exot. 2009;102:5-6.
38. Finsterer J, Kladosek A, Lubec D, et al. Bilateral thalamic stroke due to neurocysticercosis in a non-endemic area. Cerebrovasc Dis. 2001;11:354-356. (Pubitemid 32511093)
39. Rodriguez-Carbajal J, Del Brutto OH, Penagos P, et al. Occlusion of the middle cerebral artery due to cysticercotic angiitis. Stroke. 1989;20:1095-1098.
40. Aditya GS, Mahadevan A, Santosh V, et al. Cysticercal chronic basal arachnoiditis with infarcts, mimicking tuberculous pathology in endemic areas. Neuropathology. 2004;24:320-325. (Pubitemid 39664755)
41. Jha S, Kumar V. Neurocysticercosis presenting as stroke. Neurol India. 2000;48:391-394 (Pubitemid 32094211)
42. ter Penning B, Litchman CD, Heier L. Bilateral middle cerebral artery occlusions in neurocysticercosis. Stroke. 1992;23:280-283.
43. Levy AS, Lillehei KO, Rubinstein D, et al. Subarachnoid neurocysticercosis with occlusion of the major intracranial arteries: casereport. Neurosurgery. 1995;36:183-188.
44. Mc Cormick GF, Giannotta SL, Zee C-S, et al. Carotid occlusion in cysticercosis. Neurology. 1983;33:1078-1080. (Pubitemid 13030199)
45. Torrealba G, Del Villar S, Tagle P, et al. Cysticercosis of the central nervous system: clinical and therapeutic considerations. JNeurol Neurosurg Psychiatry. 1984;47:784-790. (Pubitemid 14059367)
46. Kohli A, Gupta R, Kishore J. Anterior cerebral artery territory infarction in neurocysticercosis: evaluation by MR angiography and in vivo proton MR spectroscopy. Pediatr Neurosurg. 1997; 26:93-96. (Pubitemid 27500391)
47. Bickerstaff ER. Cerebral cysticercosis: common but unfamiliar manifestations. BMJ. 1955;1:1055-1058
48. Chavarŕa A, Fleury A, Garća E, et al. Relationship between the clinical heterogeneity of neurocysticercosis and the immune-inflammatory profiles. Clin Immunol. 2005;116:271-278.
49. Del Brutto OH. Cysticercosis and cerebrovascular disease: a review. J Neurol Neurosurg Psychiatry. 1992;55:252-254.
50. Oluigbo CO, Choudhari KA, Flynn P, et al. Meningioma presenting with transient ischaemic attacks. Br JNeurosurg. 2004; 18:635-637. (Pubitemid 40101083)
51. Krakauer JW. The complex dynamics of stroke onset and progression. Curr Opin Neurol. 2007;20:47-50. (Pubitemid 46090142)
52. Tellez-Zenteno JF, Negrete-Pulido O, Cantú C, et al. Hemorrhagic stroke associatedto neurocysticercosis.Neurologia. 2003;18:272-275.
53. Soto-Hernandez JL, Andrade SG, Rojas-Echeverri LA, et al. Subarachnoid hemorrhage secondary to a ruptured inflammatory aneurysm: a possible manifestation of neurocysticercosis: case report. Neurosurgery. 1996;38:197-200. (Pubitemid 26002401)
54. Huang PP, Choudhri HF, Jallo G, et al. Inflammatory aneurysm and neurocysticercosis. Further evidence for a causal relationship? Case report. Neurosurgery. 2000;47:466-468. (Pubitemid 32049358)
55. Kim IY, Kim TS, Lee JH, et al. Inflammatory aneurysm due to neurocysticercosis. J Clin Neurosci. 2005;12:585-588.
56. Arauz A, López M, Cantú C, et al. Nonaneurysmal subarachnoid hemorrhage. Study of long-term follow-up Neurologia. 2007;22: 502-506. (Pubitemid 350114918)
57. Zee C, Segall HD, Miller C. Unusual neuroradiological features of intracranial cysticercosis. Radiology. 1980;137:397-407. (Pubitemid 10008912)
58. Kannoth S, Thomas SV. Intracranial microbial aneurysm (infec-tious aneurysm): current options for diagnosis and management. Neurocrit Care. 2009;11:120-129.
59. Ducruet AF, Hickman ZL, Zacharia BE, et al. Intracranial infectious aneurysms: a comprehensive review. Neurosurg Rev. 2010;33:37-46.
60. Del Brutto OH. Is the course of neurocysticercosis modified by treatment with anthelmintic agents? Arch Intern Med. 1997;157: 128-130. (Pubitemid 27027084)
61. Del Brutto OH, Roos KL, Coffey CS, et al. Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and prazi-quantel. Ann Intern Med. 2006;145:43-51. (Pubitemid 46780606)
62. Bang OY, Heo JH, Choi SA, et al. Large cerebral infarction during praziquanteltherapy inneurocysticercosis. Stroke. 1997;28:211-213. (Pubitemid 27039488)
63. Fong GC, Cheung RT. Caution with praziquantel in neuro-cysticercosis. Stroke. 1997;28:1648-1649
64. Arteaga-Rodŕguez C, Naréssi-Munhoz AH, Hernández- Fustes OJ. Extensive cerebral infarction and neurocysticercosis. Rev Neurol. 2004;39:583. (Pubitemid 39472018)
65. Garg RK. Medical management of neurocysticercosis. Neurol India. 2001;49:329-337. (Pubitemid 34116274)
66. Singh G, Prabhakar S. The effects of antimicrobial and antiepileptic treatment on the outcome ofepilepsy associated with central nervous system (CNS) infections. Epilepsia. 2008; 49(Suppl 6):42-46.
67. Nash TE, Singh G, White AC, et al. Treatment of neuro-cysticercosis: current status and future research needs. Neurology. 2006;67:1120-1127. (Pubitemid 44563815)
68. Del Brutto OH, Wadia NH, Dumas M, et al. Proposal ofdiagnostic criteria for human cysticercosis and neurocysticercosis. J Neurol Sci. 1996;142:1-6. (Pubitemid 26340400)
69. Sinha S, Sharma BS. Neurocysticercosis: a review of current status and management. J Clin Neurosci. 2009;16:867-876.
70. Rajshekhar V. Surgical management of neurocysticercosis. Int J Surg. 2010;8:100-104
71. Garća HH, Evans CA, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002;15:747-756.
72. Mahanty S, Garcia HH. Cysticercosis and neurocysticercosis as pathogens affecting the nervous system. Prog Neurobiol. 2010;91: 172-184.
73. Góngora-Rivera F, Soto-Hernández JL, Guevara P, et al. In neurocysticercosis, CSF cytokines correlate with cerebral blood flowvelocities. Neurology. 2008;71:1119-1122.
74. Silbert PL, Gubbay SS, Khangure M. Distinctive MRI findings in a case ofneurocysticercosis. Med JAust. 1993;159:185-186. (Pubitemid 23235827)
75. Cantú C, Villarreal J, Soto JL, et al. Cerebral cysticercotic arteritis: detection and follow-up by transcranial Doppler. Cerebrovasc Dis. 1998;8:2-7. (Pubitemid 28046069)
76. Adams HP Jr, Adams RJ, Brott T, et al. Stroke Council of the American Stroke Association. Guidelines for the early manage-ment of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003;34:1056-1083. (Pubitemid 36402991)
77. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Circulation. 2007; 115:e478-e534.
78. Willingham AL III, Engels D. Control of Taenia solium cysticercosis/taeniosis. Adv Parasitol. 2006;61:509-566. (Pubitemid 43792517)
79. Wardlaw JM, Murray V, Berge E, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009;4: CD000213.
80. Naess H, Nyland HI, Thomassen L, et al. Long-term outcome of cerebral infarction in young adults. Acta Neurol Scand. 2004; 110:107-112 (Pubitemid 39044047)
81. Centers for Disease Control. Recommendations of the interna-tional task force for disease eradication. Morb Mortal Wkly Rep. 1993;42:1-38.
82. Sotelo J. Neurocysticercosis: eradication of cysticercosis is an attainable goal. BMJ. 2003;326:511-512.